Kathleen E Corey1, Rebecca Pitts2, Michelle Lai3, Joseph Loureiro2, Ricard Masia4, Stephanie A Osganian5, Jenna L Gustafson5, Matthew M Hutter6, Denise W Gee6, Ozanan R Meireles6, Elan R Witkowski6, Shola M Richards2, Jaison Jacob2, Nancy Finkel2, Debby Ngo7, Thomas J Wang8, Robert E Gerszten9, Chinweike Ukomadu2, Lori L Jennings2. 1. Division of Gastroenterology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA. Electronic address: kcorey@partners.org. 2. Novartis Institutes for BioMedical Research, Cambridge, MA, USA. 3. Division of Hepatology, Beth Israel Deaconess Hospital (BIDMC) and HMS, Boston, MA, USA. 4. Department of Pathology, MGH and HMS, Boston, MA, USA. 5. Division of Gastroenterology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA. 6. Department of Surgery, MGH and HMS, Boston, MA, USA. 7. Department of Pulmonary/Critical Care, Cardiovascular Institute, BIDMC and HMS, Boston, MA, USA. 8. Department of Cardiology, Vanderbilt University School of Medicine, Nashville, TN USA. 9. Division of Cardiovascular Medicine and Cardiovascular Institute, BIDMC and HMS, Boston, MA, USA.
Abstract
BACKGROUND & AIMS: Identifying fibrosis in non-alcoholic fatty liver disease (NAFLD) is essential to predict liver-related outcomes and guide treatment decisions. A protein-based signature of fibrosis could serve as a valuable, non-invasive diagnostic tool. This study sought to identify circulating proteins associated with fibrosis in NAFLD. METHODS: We used aptamer-based proteomics to measure 4,783 proteins in 2 cohorts (Cohort A and B). Targeted, quantitative assays coupling aptamer-based protein pull down and mass spectrometry (SPMS) validated the profiling results in a bariatric and NAFLD cohort (Cohort C and D, respectively). Generalized linear modeling-logistic regression assessed the ability of candidate proteins to classify fibrosis. RESULTS: From the multiplex profiling, 16 proteins differed significantly by fibrosis in cohorts A (n = 62) and B (n = 98). Quantitative and robust SPMS assays were developed for 8 proteins and validated in Cohorts C (n = 71) and D (n = 84). The A disintegrin and metalloproteinase with thrombospondin motifs like 2 (ADAMTSL2) protein accurately distinguished non-alcoholic fatty liver (NAFL)/non-alcoholic steatohepatitis (NASH) with fibrosis stage 0-1 (F0-1) from at-risk NASH with fibrosis stage 2-4, with AUROCs of 0.83 and 0.86 in Cohorts C and D, respectively, and from NASH with significant fibrosis (F2-3), with AUROCs of 0.80 and 0.83 in Cohorts C and D, respectively. An 8-protein panel distinguished NAFL/NASH F0-1 from at-risk NASH (AUROCs 0.90 and 0.87 in Cohort C and D, respectively) and NASH F2-3 (AUROCs 0.89 and 0.83 in Cohorts C and D, respectively). The 8-protein panel and ADAMTSL2 protein had superior performance to the NAFLD fibrosis score and fibrosis-4 score. CONCLUSION: The ADAMTSL2 protein and an 8-protein soluble biomarker panel are highly associated with at-risk NASH and significant fibrosis; they exhibited superior diagnostic performance compared to standard of care fibrosis scores. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of liver disease worldwide. Diagnosing NAFLD and identifying fibrosis (scarring of the liver) currently requires a liver biopsy. Our study identified novel proteins found in the blood which may identify fibrosis without the need for a liver biopsy.
BACKGROUND & AIMS: Identifying fibrosis in non-alcoholic fatty liver disease (NAFLD) is essential to predict liver-related outcomes and guide treatment decisions. A protein-based signature of fibrosis could serve as a valuable, non-invasive diagnostic tool. This study sought to identify circulating proteins associated with fibrosis in NAFLD. METHODS: We used aptamer-based proteomics to measure 4,783 proteins in 2 cohorts (Cohort A and B). Targeted, quantitative assays coupling aptamer-based protein pull down and mass spectrometry (SPMS) validated the profiling results in a bariatric and NAFLD cohort (Cohort C and D, respectively). Generalized linear modeling-logistic regression assessed the ability of candidate proteins to classify fibrosis. RESULTS: From the multiplex profiling, 16 proteins differed significantly by fibrosis in cohorts A (n = 62) and B (n = 98). Quantitative and robust SPMS assays were developed for 8 proteins and validated in Cohorts C (n = 71) and D (n = 84). The A disintegrin and metalloproteinase with thrombospondin motifs like 2 (ADAMTSL2) protein accurately distinguished non-alcoholic fatty liver (NAFL)/non-alcoholic steatohepatitis (NASH) with fibrosis stage 0-1 (F0-1) from at-risk NASH with fibrosis stage 2-4, with AUROCs of 0.83 and 0.86 in Cohorts C and D, respectively, and from NASH with significant fibrosis (F2-3), with AUROCs of 0.80 and 0.83 in Cohorts C and D, respectively. An 8-protein panel distinguished NAFL/NASH F0-1 from at-risk NASH (AUROCs 0.90 and 0.87 in Cohort C and D, respectively) and NASH F2-3 (AUROCs 0.89 and 0.83 in Cohorts C and D, respectively). The 8-protein panel and ADAMTSL2 protein had superior performance to the NAFLD fibrosis score and fibrosis-4 score. CONCLUSION: The ADAMTSL2 protein and an 8-protein soluble biomarker panel are highly associated with at-risk NASH and significant fibrosis; they exhibited superior diagnostic performance compared to standard of care fibrosis scores. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of liver disease worldwide. Diagnosing NAFLD and identifying fibrosis (scarring of the liver) currently requires a liver biopsy. Our study identified novel proteins found in the blood which may identify fibrosis without the need for a liver biopsy.
Authors: Digna R Velez; Bill C White; Alison A Motsinger; William S Bush; Marylyn D Ritchie; Scott M Williams; Jason H Moore Journal: Genet Epidemiol Date: 2007-05 Impact factor: 2.135
Authors: Morten A Karsdal; Samuel J Daniels; Signe Holm Nielsen; Cecilie Bager; Daniel G K Rasmussen; Rohit Loomba; Rambabu Surabattula; Ida Falk Villesen; Yi Luo; Diane Shevell; Natasja S Gudmann; Mette J Nielsen; Jacob George; Rose Christian; Diana J Leeming; Detlef Schuppan Journal: Liver Int Date: 2020-02-19 Impact factor: 5.828
Authors: W Taylor Kimberly; John F O'Sullivan; Anjali K Nath; Michelle Keyes; Xu Shi; Martin G Larson; Qiong Yang; Michelle T Long; Ramachandran Vasan; Randall T Peterson; Thomas J Wang; Kathleen E Corey; Robert E Gerszten Journal: JCI Insight Date: 2017-05-04
Authors: Stephen A Harrison; Vlad Ratziu; Jérôme Boursier; Sven Francque; Pierre Bedossa; Zouher Majd; Geneviève Cordonnier; Fouad Ben Sudrik; Raphael Darteil; Roman Liebe; Jérémy Magnanensi; Yacine Hajji; John Brozek; Alice Roudot; Bart Staels; Dean W Hum; Sophie Jeannin Megnien; Suneil Hosmane; Noémie Dam; Pierre Chaumat; Rémy Hanf; Quentin M Anstee; Arun J Sanyal Journal: Lancet Gastroenterol Hepatol Date: 2020-08-05
Authors: Samuel J Daniels; Diana J Leeming; Mohammed Eslam; Ahmed M Hashem; Mette J Nielsen; Aleksander Krag; Morten A Karsdal; Jane I Grove; Indra Neil Guha; Takumi Kawaguchi; Takuji Torimura; Duncan McLeod; Jun Akiba; Philip Kaye; Bastiaan de Boer; Guruprasad P Aithal; Leon A Adams; Jacob George Journal: Hepatology Date: 2019-03 Impact factor: 17.425
Authors: Larry Gold; Deborah Ayers; Jennifer Bertino; Christopher Bock; Ashley Bock; Edward N Brody; Jeff Carter; Andrew B Dalby; Bruce E Eaton; Tim Fitzwater; Dylan Flather; Ashley Forbes; Trudi Foreman; Cate Fowler; Bharat Gawande; Meredith Goss; Magda Gunn; Shashi Gupta; Dennis Halladay; Jim Heil; Joe Heilig; Brian Hicke; Gregory Husar; Nebojsa Janjic; Thale Jarvis; Susan Jennings; Evaldas Katilius; Tracy R Keeney; Nancy Kim; Tad H Koch; Stephan Kraemer; Luke Kroiss; Ngan Le; Daniel Levine; Wes Lindsey; Bridget Lollo; Wes Mayfield; Mike Mehan; Robert Mehler; Sally K Nelson; Michele Nelson; Dan Nieuwlandt; Malti Nikrad; Urs Ochsner; Rachel M Ostroff; Matt Otis; Thomas Parker; Steve Pietrasiewicz; Daniel I Resnicow; John Rohloff; Glenn Sanders; Sarah Sattin; Daniel Schneider; Britta Singer; Martin Stanton; Alana Sterkel; Alex Stewart; Suzanne Stratford; Jonathan D Vaught; Mike Vrkljan; Jeffrey J Walker; Mike Watrobka; Sheela Waugh; Allison Weiss; Sheri K Wilcox; Alexey Wolfson; Steven K Wolk; Chi Zhang; Dom Zichi Journal: PLoS One Date: 2010-12-07 Impact factor: 3.240
Authors: Marie Boyle; Dina Tiniakos; Jorn M Schattenberg; Vlad Ratziu; Elisabetta Bugianessi; Salvatore Petta; Claudia P Oliveira; Olivier Govaere; Ramy Younes; Stuart McPherson; Pierre Bedossa; Mette J Nielsen; Morten Karsdal; Diana Leeming; Stuart Kendrick; Quentin M Anstee Journal: JHEP Rep Date: 2019-07-04